CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
Key Highlights
- ➤CytomX (CTMX) will report third-quarter 2026 financial results November 5 after market close
- ➤Conference call and webcast scheduled for 5:00 p.m. ET following results
- ➤Clinical-stage pipeline includes Varseta-M and CX-801 oncology candidates
Expert Statements
Chris Ogden, SVP, Chief Financial Officer of CytomX Therapeutics
“CytomX Therapeutics, Inc.”
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
Get started
Create a free account to read the full story.